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Abstract
Background: Right ventricular failure is a serious complication after left ventricular assist device placement.
Case Presentation: A 70-year-old male in decompensated heart failure with right ventricular failure after the
placement of a left ventricular assist device. A single dual-lumen PROTEKDuo cannula was inserted percutaneously via
the internal jugular vein to draw blood from the right atrium and return into the pulmonary artery using the CentriMag
system, by passing the failing ventricle. The patient was successfully weaned from right ventricular assist device.
Conclusions: In comparison to two-cannula conventional procedures, this right ventrivular assist device system
improves patient rehabilitation and minimizes blood loss and risk of infection, while shortening procedure time and
improving clinical outcomes in right ventricular failure.
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Background
Perioperative right ventricular failure (RVF) is associated
with a poor prognosis and high mortality [1]. After left
ventricular assist device (LVAD) placement, 7–15 % of
patients develop significant RVF that requires temporary
right ventricular assist device (RVAD) placement [1, 2].
Temporary RVAD placement has previously required
additional operations contributing to less satisfactory re-
sults compared to isolated continuous flow LVADs [3].
Traditionally, extracorporeal membrane oxygenation
(ECMO) and RVAD insertion are established through
sternotomy with direct right atrial and pulmonary artery
(PA) cannulation or PA cannulation via graft. Other centers
have proposed percutaneous RVAD placement through the
right internal jugular vein (IJV) as well as femoral vein
cannulation [4]. Impella RP (Abiomed, Inc, Danvers,
MA, USA) is a temporary RVAD with percutaneous ap-
proach, however the access site is the femoral vein lim-
iting patient ambulation and body position [5].
The dual-lumen PROTEKDuo (CadiacAssist, Inc.
Pittsburgh, PA, USA) contains omnidirectional inflow
and outflow ports for simultaneous drainage and reinfu-
sion of blood [5]. Through a minimally-invasive approach
via the IJV, the dual-lumen PROTEKDuo is positioned to
draw blood from the right atrium and propel it into the
PA, thereby bypassing the failing ventricle (Fig. 1).
This case describes successful restoration of RV func-
tion using a percutaneous single PROTEKDuo cannula
through the right IJV with the CentriMag (Thoratec
Corp, Pleasanton CA, USA) system and avoidance of re-
sternotomy for decannulation.
Case presentation
A 70-year-old male underwent Heartmate II (HMII)
placement as a destination therapy. He had a history of
atrial fibrillation, severe mitral stenosis, tricuspid regurgi-
tation (TR), and non-ischemic cardiomyopathy (NICM).
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He was hospitalized with acute on chronic biventricular
decompensated heart failure (EF 20–25 %) (NYHA IV,
INTERMACS 2, ACC/AHA Stage D) four years after a
mitral valve replacement and tricuspid valve repair. He
had diabetes mellitus type 2, COPD, chronic kidney dis-
ease with baseline creatinine of 1.4–1.7 and on IV Lasix.
He was suspected of multifocal pneumonia and an overall
sequela of ongoing progressive advanced heart failure.
Three weeks prior to LVAD implant, right heart cath
showed RA of 10 mmHg, RV of 60/10 mmHg, PA of 60/
28 (38) mmHg, PAWP of 22 mmHg, V-wave of 40 mmHg,
Trans-Pulmonary Gradient of 16 mmHg, Thermodilution
Cardiac Output of 4.85 L/min; Cardiac Index of 2.47 L/
min/m2, Fick’s CO of 5.69 L/min and CI of 2.9 L/min/m2,
PVR-Pulmonary Vascular Resistance of 3 Wood units, and
SVR-Systemic Vascular Resistance of 627 dyn.s.cm-5.
MRI Study showed (BSA-normalized values): RV EDV:
310 ml (156 ml normalized); RV ESV: 239 ml (120 ml
normalized); RV SV: 72 ml (36 ml normalized); RV EF
of 23 %); CCO of 5.8 L/min; CCI of 2.9 L/min/m2.
A re-do median sternotomy was performed and cardio-
pulmonary bypass established with bicaval cannulation.
After a repeat of tricuspid value repair with Kay’s stitch
due to severe regurgitation from annular dilatation, a
HMII was inserted in standard fashion. The LVAD was
initiated (4.5 L/min, 8200 rpms) but his RV function
was acceptable; thus requiring inotropes support
(DOB-5 mcg/kg/min; norepinephrine-15 mcg/kg/min,
vasopressin-0.04 units/min and inhaled nitric oxide
(iNO) of 40. Swan-Ganz catheter showed CVP of
27 mmHg, PA of 59/27(37) mmHg, CCO of 5.4 L/min,
CCI of 2.6 L/min/m2, and SVR of 755.56 dyn.s.cm-5.
TEE demonstrated descent RV function and he was
extubated within 24-hours post-operation. Continuous
renal replacement therapy (CRRT) was initiated on
postoperative day (POD) two for his metabolic acidosis
and anuria. The patient was re-intubated and sedated
POD3 due to respiratory failure. He received one and
two units of packed RBC on POD1 and POD3 respectively.
No FFP, CRYO, or platelets were given. Epinephrine was
started for RV support and LVAD flow decreased (5.0 L/min,
8400 rpms). Despite escalating vasopressor and ino-
tropic support (Epi-2mcg/kg/min, DOB-5mcg/kg/min,
Mil-0.125mcg/kg/min, norepinephrine-3mcg/kg/min, vaso-
0.04units/min, Phenylephrine-75mcg/kg/min) echocardiog-
raphy demonstrated refractory pulmonary hypertension
and RVF with PVR of 3 Wood units. Swan-Ganz catheter
showed CVP of 17 mmHg, PA of 42/22(29) mmHg, CCO
of 5.8 L/min, CCI of 3.1 L/min/m2, SVR of 575 dyn.s.cm-5.
A percutaneous CentriMag RVAD placement with a 29
Fr PROTEKDuo cannula was performed in the cardiac
catheterization lab on POD6 (Fig. 2). Under fluoroscopy, a
0.025 T-J wire was passed through the Swan-Ganz
catheter and subsequently exchanged for a stiffer 0.035
inch T-J wire, extending from the IJV, via brachiocepha-
lic vein and superior vena cava, into the right atrium
(RA) and ventricle, then through the pulmonary valve
into the PA. The cannula was passed over the wire and
positioned in the RA with outflow port beyond the pul-
monary valve. The proximal and distal cannulae were
Fig. 1 PROTEKDuo Cannula. The PROTEKDuo Cannula is a double lumen cannula. The proximal holes drain blood from right atrium to the pump.
The distal holes return blood to the pulmonary artery
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then connected to the CentriMag system and RVAD was
established with stable flow (3.5 L/min, 3800 rpms). LVAD
flow was also increased (7 L/min, 8800 rpms). Cardiac
output and hemodynamics improved exponentially after
RVAD placement; reducing the need for pharmacologic
support. Sildenafil and iNO were continued. Stabilized RV
function overcame the patient’s pulmonary hypertension,
reestablishing adequate pulmonary circulation and suffi-
cient LV filling thereby enabling proper LVAD function
and increased cardiac output. RVAD supported RV recov-
ery facilitating the removal of 13 liters of fluid via CRRT,
improving patient’s volume status. The patient’s heart was
stable before device wean and decannulation took place
on POD11.
Conclusion
High mortality and a poor prognosis with RVF after
LVAD implant indicate that treatment of RVF is an import-
ant factor in recovery from HF [6]. The approach described
herein further improves upon previously documented min-
imally invasive procedures [4]. The PROTEKDuo was posi-
tioned via the IJV with inflow port in the RA and outflow
port in the PA. Using the CentriMag system, RVAD was
established to augment the failing ventricle. RV function
was stabilized, restoring hemodynamics, overcoming the
patient’s pulmonary hypertension, and allowing for 13 liters
of fluid removal via CRRT. With improved RV function,
the device was weaned and the patient decannulated eleven
days later.
Conventional RVAD insertion often requires repeat
sternotomy. In comparison, the percutaneous approach
decreases blood loss and potential coagulopathy. Fur-
thermore, the RV can be decompressed without chest
opening. However, sometimes the chest is left open for
coagulopathy and RV dilation, potentially increasing the
risk of infection [7]. Surgical implantation has effectively
facilitated longer support times than percutaneous RVADs,
though utilizing femoral cannulation. Other percutaneous
RVAD procedures involve separate inflow and outflow sites,
generally including femoral cannulation [5]. The use of the
dual-lumen PROTEKDuo requires only a single insertion
site in the right jugular vein, which allows for expedited
mobility and rehabilitation and minimizes lower limb ische-
mia. The cannula is a 510 K clearance which stated “a sin-
gle cannula for both venous drainage and reinfusion of
blood via internal jugular vein during extracorporeal life
support (ECLS) procedure”. This 510 K approval process
equals this product to the Avalon cannula made by Maquet.
To our best knowledge, there is no FDA approval of ECLS
comprising of pump, oxygenator, and cannula. Therefore,
the use of PROTEKDuo Cannula with CentriMag pump is
appropriately “off-label”. We cautioned that the maker of
these cannula has the right not to sell the cannula. Other
centers have proposed an RVAD implantation technique
that does not necessitate resternotomy at the time of RVAD
removal, but the concern of bleeding and infection from
the Dacron graft site remains [7].
There are many advantages to using this PROTEKDuo
Cannula as an RVAD with the CentriMag. First, the
CentriMag is a reliable temporary pump and this off-
pump catherization procedure can be performed in a short
timeframe (<1 hours), minimizing blood loss, transfusion
and postoperative inflammation. Furthermore, avoiding a
median sternotomy, preserves the sternum for a later chest
re-entry or heart transplant. Patients can be extubated early,
and can ambulate early post-operatively without any groin
instrumentation or cannulation; an advantage to previously
reported percutaneous RVAD insertion [8]. Furthermore,
the combination of CentriMag and PROTEKDuo can-
nula would allow us the option of slicing in an Oxygen-
ator should the patient require one. Also, the cannula
can robustly decompress the right heart allowing ven-
tricular recovery and decreased clot formation because
of the constant flow through the right ventricle.
Traditional sternal re-entry under emergent conditions
is treacherous and cumbersome. This procedure has great
utility in patients with previous cardiac surgery. The
procedure is technically easy to establish RVAD support,
provides efficient support and decompression in cardio-
genic shock in coagulopathic patients. The disadvantage
of having only a single cannula size, limits patients with a
larger BSA. Also, Insertion of the cannula can be tricky re-
quiring fluoroscopy and stiff guidewire to properly tunnel
Fig. 2 Placement of the PROTEKDuo Cannula. The PROTEKDuo
cannula was placed from the right internal jugular vein extending
through the right ventricle toward the pulmonary artery main trunk.
The white arrow indicates the tip of cannula
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the cannula to the PA. Finally, we utilize heparin for antic-
oagulation under guidance of Rotational Thromboelasto-
metry (ROTEM).
In conclusion, percutaneous PROTEKDuo cannula inser-
tion with CentriMag system has provided a novel approach
to establish RVAD support in a timely and minimally inva-
sive technique. This method avoids unnecessary blood
transfusion and resternotomy. Further study is warranted
to further evaluate superiority over conventional RVAD
approach.
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